Canakinumab as Adjuvant Therapy in Patient

Canakinumab as Adjuvant Therapy in Patients With Completely ...

In an exploratory analysis of the CANTOS trial, reductions in lung cancer incidence and mortality were seen, which led to the hypothesis that ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

... canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients ... Canakinumab as Adjuvant Therapy in Patients With Completely ...

MO01.22 Canakinumab as Adjuvant Therapy in Patients with ...

Background. In the CANTOS study, canakinumab (selective IL-1β inhibitor) treatment was associated with reduced incidence and mortality from NSCLC in patients ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, ...

CANOPY-A: A phase III, placebo-controlled study of canakinumab ...

CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC · Abstract · Article metrics.

Adjuvant Canakinumab in Completely Resected NSCLC

Grade ≥ 3 adverse events were reported in 20.8% of patients in the canakinumab group and 19.6% of the placebo group. Adverse events led to ...

Novartis provides update on Phase III CANOPY-A study evaluating ...

These positive signals supported the study of canakinumab as adjuvant treatment for early lung cancer,” said Jeff Legos, Executive Vice ...

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as ...

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).

Canakinumab as Adjuvant Therapy in Patients with Completely ...

TP137. TP137 THORACIC ONCOLOGY: DIAGNOSIS AND TREATMENT: IP, SURGERY, AND RADIATION · Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non- ...

Abstract CT255: Canakinumab as adjuvant therapy in patients with ...

Background: In the CANTOS study, canakinumab (selective interleukin 1β inhibitor) treatment was associated with reduced incidence and ...

P3.16-02 Phase III Study of Canakinumab (ACZ885) as Adjuvant ...

In the Phase III Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) in patients with atherosclerosis, canakinumab was associated with a ...

Canakinumab as Adjuvant Therapy in Patient - ATS Journals

Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial. A. Spira1, A. Ardizzoni2, F. Barlesi3, B ...

Canakinumab as Adjuvant Therapy in Patients With Completely ...

CONCLUSION CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with ...

Novartis provides update on Phase III study evaluating ...

CANOPY-A, another Phase III study, is investigating canakinumab as an adjuvant therapy and has enrolled more than 950 patients to date and is ...

Synergistic effect of canakinumab with epidermal growth factor ...

It is possible that IL-1β blockade may be effective in lung cancer treatment in the presence of oncogenic driver mutations, which means that ...

Abstract LBA039: Canakinumab as Adjuvant Therapy in Patients ...

Abstract. Background: In the CANTOS study, canakinumab (selective interleukin 1β inhibitor) treatment was associated with reduced incidence and ...

Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC

After the data cutoff, 21.4% of patients receiving canakinumab were still on treatment compared with 19.9% receiving placebo. Approximately ...

a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients ...

Related trials · PD01. · CANOPY-A: a phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC.

Primary End Point of Improved DFS Not Met With Adjuvant ...

Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small ...

Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in ...

OncLive 2022 - Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC open_in_new ... Canakinumab is a high-affinity antibody directed against interleukin (IL)- ...